BioVie Inc. (BIVI )

Currency in USD Disclaimer

$1 -$0.35 (-25.98%)

Closed 08/07/2026

Day's Range

$0.98

$1.23

52 wk Range

$1.06

$7.17

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Symbol BIVI
Company BioVie Inc.
Price $1
Changes Percentage -25.98
Change -0.3507
Day Low $0.98
Day High $1.23
Year High $7.17
Year Low $1.06
Market Cap $9,879,809
Price Avg 50 EMA (D) $1.68
Price Avg 200 EMA (D) $1.5
Exchange NASDAQ
Volume 15,665
Average Volume 163,444
Open $1.22
Previous Close $1.35
EPS -2.69
PE -0.49
Earnings Announcement 2026-09-02 12:00:00
Shares Outstanding $7,541,839

Company brief: BIOVIE INC. (BIVI )

Sector Healthcare
Industry Biotechnology
CEO Mr. Cuong Viet Do M.B.A.
Website https://bioviepharma.com
Headquarters US
Employees (FY) N/A
Founded 09-18-2020
ISIN US09074F2074

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

BIVI Corporation News

Apple App Store revenue ticks up despite falling downloads

August 6, 2026 at 11:43 am ET

proactiveinvestors.com -- Apple Inc (NASDAQ:AAPL, XETRA:APC) App Store revenue rose 0.6% year-over-year in the first 35 days of its fiscal fourth quarter to $3.4 billion, up from......

Uber price target lowered by Bank of America despite higher earnings outlook

August 6, 2026 at 11:33 am ET

proactiveinvestors.com -- Uber Technologies Inc (NYSE:UBER, XETRA:UT8) saw its price target lowered to $101 from $103 by Bank of America, which maintained a ‘Buy’ rating following......

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

August 6, 2026 at 9:05 am ET

proactiveinvestors.com -- BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in bl...

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease

August 6, 2026 at 7:30 am ET

globenewswire.com -- Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well ...

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

June 5, 2026 at 3:31 pm ET

prnewswire.com -- Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...